Power Law company profile

Ypsomed

Health Tech & Medtech · Bern, Switzerland · Founded 2003 · IPO 2004 Unicorn

Innovative, high-quality and reliable products and services which allow patients to administer their own medication in a safe and simple way

Valuation

$3.63B

Market cap · May/2026

Revenue

$686M

Latest reported FY

EBITDA

$303M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where Ypsomed has talent and traffic

AI talent share

0.1% of workforce is AI talent
(2 of 1,357 staff)

Core AI00%

Other AI20.15%

Non-AI workforce1,35599.85%

Workforce by country

26 countries with
team presence

🇨🇭 Switzerland78.3%

🇩🇪 Germany4.6%

🇪🇸 Spain3.2%

🇫🇷 France3%

🇬🇧 United Kingdom1.5%

Top 5 of 26 shown

Patent intelligence

$92M patent portfolio · 189 active families

Estimated portfolio value

$92M

2.5% of market cap · 5.5× smaller than top peer Insulet ($502M)

189 active patent families

Where Ypsomed innovates Biomedical engineeringInjection devicePharmaceutical drugMechanical engineeringPhysics

Where Ypsomed concentrates vs peers

Each axis is a top-10 topic across Ypsomed and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ypsomed

An AI-synthesized read of the highest-engagement posts about Ypsomed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ypsomed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles